Search Results
Your search for The ASCO Post matches 17395 pages
Showing 12551 - 12600Cervical Cancer Prevention Badly Needed in India
With the advent of the Papanicolaou (Pap) test and population-based screening, along with the development of the human papillomavirus (HPV) vaccine, cervical cancer has become a largely preventable disease for many. However, in India, cervical cancer is a leading cause of cancer mortality. To...
Ixazomib: A Relevant Addition to Myeloma Therapy
In 2015, four new drugs were approved for the treatment of multiple myeloma by the U.S. Food and Drug Administration: panobinostat (Farydak), daratumumab (Darzalex), elotuzumab (Empliciti), and ixazomib (Ninlaro). Of them, the first three are drugs with unique new targets, whereas ixazomib is the...
NCCN Awards Research Grants to Support Studies of Mirvetuximab Soravtansine in Various Cancers
The National Comprehensive Cancer Network® (NCCN) Oncology Research Program (ORP) has awarded eight grants to investigators to support clinical and preclinical studies of mirvetuximab soravtansine (IMGN853) and advance scientific knowledge of its uses in ovarian and other folate receptor alpha...
Medical Decision-Making: At the Heart of Care for Older Patients With Cancer
Although oncology has moved toward a personalized approach to care, medical decision-making within the context of multidisciplinary care has broad public health implications. To shed light on this and other relevant issues, The ASCO Post recently spoke with William Dale, MD, PhD, of the University ...
David Spigel, MD, Appointed as Sarah Cannon Chief Scientific Officer
Sarah Cannon announced the promotion of David Spigel, MD, as Chief Scientific Officer. The new appointment supports the continuous expansion of clinical research and drug development programs, which provides patients with access to novel therapies at the earliest stages. As Chief Scientific...
Expert Point of View: Samir Gupta, MD
Samir Gupta, MD, Associate Professor of Medicine at the University of California San Diego, who has led trials of colorectal cancer screening, commented on this study for The ASCO Post. Although there are approximately 138,000 new colorectal cancer diagnoses a year in the United States, only...
Expert Point of View: Peter C. Enzinger, MD
Not so FAST? The study discussant Peter C. Enzinger, MD, Director of the Center for Esophageal and Gastric Cancer at Dana-Farber/Brigham and Women’s Cancer Center, Boston, viewed the findings of the FAST trial as promising but voiced several considerations, as did Gulam A. Manji, MD, PhD,...
Vast Differences Globally in Cancer Drug Retail Prices
A pilot study revealed large differences in median retail prices for 23 cancer drugs in 7 different countries, with the highest retail prices identified in the United States and the lowest, in India and South Africa. Notably, after the monthly drug price is expressed as a percentage of domestic...
CAR T-Cell Therapy Using Double Target Aimed at Solid Tumors in Preclinical Models
Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. Now, in a report published...
Influence of Age and Comorbidities on Rates of Colorectal Cancer Screening in the Elderly
Colorectal cancer (CRC) is a common and costly disease, largely of the elderly, with nearly 25% of cases diagnosed among patients aged 75–84 years. However, but the guidelines for CRC screening of Americans aged 75 or older vary according to the source. In a study published by Klabunde et al...
ASCO Announces New Award Honoring Visionary Leader Allen S. Lichter, MD, FASCO
During the 2016 Annual Meeting, ASCO announced the creation of the Allen S. Lichter Visionary Leader Award to recognize ASCO members who have transformed the oncology field or significantly advanced the mission of ASCO, the Conquer Cancer Foundation, or CancerLinQ, LLC, through their leadership,...
Expert Point of View: Tiffany A. Traina, MD, and Larry Norton, MD
Study discussant Tiffany A. Traina, MD, Clinical Director of the Breast Medicine Service and Associate Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor of Medicine at Weill Cornell Medicine, commented, “The overall trial results demonstrate that not only is docetaxel...
ASCO Releases the Updated Version of Its Value Framework
Last June, ASCO published its initial concept for a value framework in the Journal of Clinical Oncology (JCO).1 The framework, developed by ASCO’s Value in Cancer Care Task Force, is designed to provide a standardized approach to assist physicians and patients in assessing the “value” of a new...
For High-Risk Neuroblastoma, Two Transplants May Be Better Than One
In children with high-risk neuroblastoma, tandem autologous stem cell transplant (ASCT) improved event-free survival rates in the ANBL0532 trial from the Children’s Oncology Group. The study was presented at the plenary session of the 2016 ASCO Annual Meeting by Julie R. Park, MD, of Seattle...
Autologous Stem Cell Transplantation Offers Safe, Effective Option for Patients With HIV-Associated Lymphoma
A phase II, multicenter trial published by Alvarnas et al in Blood challenges the generally held belief that individuals with human immunodeficiency virus (HIV) and aggressive lymphoma are not candidates for standard treatment. According to the researchers, people with HIV-associated lymphoma who...
Patient Navigators Improve Comprehensive Cancer Center Screening Rates
A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators—individuals who assist patients in receiving health care services—may improve comprehensive cancer screening rates among patient populations not likely to...
Report Finds Families of Cancer Survivors Challenged by Intense, Episodic Caregiving Experiences
A new report shows that people caring for a loved one with cancer often have more intense, episodic caregiver responsibilities than those caring for someone with other health needs. The report, from the National Alliance for Caregiving in partnership with the National Cancer Institute and the...
SNMMI 2016: VASH Collimator Allows Three-Dimensional Imaging of the Breast With Less Radiation
Preliminary tests have demonstrated that a new device may enable existing breast cancer imagers to provide up to six times better contrast of tumors in the breast, while maintaining the same or better image quality and halving the radiation dose to patients. The advance is made possible by a new...
Protein Could Help Identify Chronic Graft-vs-Host Disease
A new study published by Kariminia et al in the journal Blood has identified a protein that could diagnose chronic graft-vs-host disease in patients undergoing blood and bone marrow transplantation. The work was led by researchers in the Michael Cuccione Childhood Cancer Research Program at BC...
SNMMI 2016: Pretargeted Radioimmunotherapy Eliminates Colorectal Cancer in Preclinical Studies
Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models (Scientific Paper...
SNMMI 2016: PET/CT Imaging of Prostate Cancer With Specific Agent May Be an Accurate Prebiopsy/Preoperative Guide
With surgical removal at the frontline of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society of ...
SNMMI 2016: Personalized Kidney Dosimetry Optimizes Radiotherapy Dose in Patients With Neuroendocrine Tumors
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a molecular imaging technique that allows oncologists to set patients’ radiotherapy doses right at that critical limit of delivering the most powerful dosage to neuroendocrine...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results from the SQUIRE Trial (Spanish Language Version) 
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with stage IV squamous non–small cell lung cancer. To see the English language...
SNMMI 2016: A Blood-Based Multi-Transcript Test May Predict Success of Neuroendocrine Cancer Therapy
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an investigative blood test could...
SNMMI 2016: FDG-PET Evaluates Immunotherapy for Non–Small Cell Lung Cancer
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a means of evaluating an immunotherapy that fights off non–small cell lung cancer (NSCLC) by strengthening a patient’s own immune system (Scientific Paper 134). Due to...
SNMMI 2016: CT-Based Lean Body Mass Calculations Improve Accuracy of PET for Patients With Cancer
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body...
Many Family Physicians May Be Misinformed About Lung Cancer Screening
Although clinical trials have shown that lung cancer screening using low-dose computed tomography (CT) can detect lung cancers early and reduce lung cancer mortality, less than half of family physicians in a recent survey agreed that screening reduces lung cancer–related deaths. Most were...
Adjuvant Chemotherapy in Early-Stage Non–Small Cell Lung Cancer Improves Overall Survival
The use of adjuvant chemotherapy in early-stage non–small cell lung cancer (NSCLC) patients improves overall survival and 5-year overall survival rates in patients with tumor sizes ranging from 3 to 7 cm. These findings were published by Morgensztern et al in the Journal of Thoracic...
ASCO 2016: Nivolumab Shows Promise in Refractory, Metastatic Anal Cancer
In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint inhibitor nivolumab (Opdivo) shows promise for the majority of patients with squamous cell carcinoma of the ...
ASCO 2016: Hispanic and Black Young Adults With Cancer May Be More Likely to Die of Their Disease
Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented by Colton et al at the 2016 ASCO Annual Meeting (Abstract 6557). The finding is...
ASCO 2016: Nivolumab Extends Survival for Patients With Advanced Renal Cell Carcinoma Treated Beyond Disease Progression
In a large randomized study, the immunotherapy drug nivolumab (Opdivo), an anti–PD-1 (programmed cell death protein 1) monoclonal antibody, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results ...
ASCO 2016: Cancer Diagnosed More Often in Patients With Primary Immunodeficiency Disease
Primary immunodeficiency disorders are a group of more than 300 single gene defects that affect the role of the immune system and prevent it from functioning properly. When Roswell Park Cancer Institute (RPCI) researchers evaluated the overall and site-specific incidence of cancer among patients...
Scenes From ASCO 2016
1. “The Bean” or Cloud Gate with a little ASCO color. Photo © 2016 ASCO/Todd Buchanan. 2. ASCO CEO Allen S. Lichter, MD, FASCO, introducing ASCO President Julie M. Vose, MD, MBA, FASCO, during the Opening Session of the 2016 ASCO Annual Meeting in Chicago. Photo © 2016 ASCO/Phil McCarten....
FDA Approves EGFR Mutation–Detecting Blood Test for NSCLC
The U.S. Food and Drug Administration (FDA) recently approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva). This is the first FDA-approved, blood-based genetic test that can detect EGFR gene...
MD Anderson Receives $10.6 Million From CPRIT for Lung Cancer Research
The University of Texas MD Anderson Cancer Center will receive $10.6 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT) for two collaborative studies targeting crucial issues in lung cancer. The two multi-investigator research awards, designed to support teams of...
FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has approved Netspot, the first kit for the preparation of Ga-68 dotatate injection, a radioactive diagnostic agent for positron-emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with...
ASCO Value in Cancer Care Task Force
The Value in Cancer Care Task Force was established in 2007 to educate oncologists about the importance of discussing costs associated with recommended treatments, empower patients to ask questions about the anticipated costs of their treatment options, identify the drivers of the rising costs of...
ASCO Updates Value in Cancer Care Framework
On May 31, 2016, ASCO published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al,1 defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms...
Yale Researchers Win Sokoloff Family-Melanoma Research Alliance Award
A new approach to understanding why T cells are often too weak to fight and destroy tumor cells has earned Yale Cancer Center researchers team science award from the Sokoloff Family-Melanoma Research Alliance. The $900,000 award will fund research over 3 years examining metabolic regulation of ...
Philip A. Salem, MD, Honored by President of Mexico for Cancer Care
Oncologist Philip A. Salem MD, Director Emeritus of Cancer Research at Baylor St. Luke’s Medical Center in Houston, was honored as a physician and author on April 28 by the President of Mexico Enrique Peña Nieto and his government for Dr. Salem’s lifelong commitment to cancer care worldwide. Dr....
AUA Honors Its 2016 Annual Award Winners
The American Urological Association (AUA) honored its 2016 AUA award recipients during its 111th Annual Meeting in San Diego, Calfornia. These physician researchers, educators, and organizations were honored for their contributions to the field of medicine, the specialty of urology, and the AUA....
Cheryl Taylore Lee, MD, Named Urology Chair at The Ohio State University Wexner Medical Center
The Ohio State University Wexner Medical Center has named a prominent expert in bladder cancer, Cheryl Taylore Lee, MD, to lead its urology, uro/gynecology, and uro/oncologic programs, beginning July 1, pending approval by The Ohio State University Board of Trustees. Dr. Lee will be Chair of the...
An Unusual Memoir of Cancer
“A book about the future must be written in advance. Later I won’t have the energy. So I will do it now.” So begins The Iceberg, a memoir set in Britain of a woman, Marion Coutts, whose husband was diagnosed with a brain tumor, which eventually killed him. Unfortunately, cancer memoirs flood the...
University of Maryland Greenebaum Cancer Center Designated as NCI Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Cancer Center has been awarded the National Cancer Institute’s (NCI’s) highest designation as a Comprehensive Cancer Center. The prestigious distinction recognizes the cancer center’s high caliber of scientific leadership and robust programs ...
Dana-Farber President to Receive SPARK! Award for Health Promotion
The Albert Schweitzer Fellowship (ASF) announced its selections for the 2016 SPARK! Awards. Edward J. Benz, Jr, MD, President and CEO of Dana-Farber Cancer Institute, will receive the 2016 Schweitzer Clarion Award for Health Promotion and Education. Dr. Benz is being honored for bringing...
HOPA Research Grants Announced, Totaling Nearly $60,000 in Funding
The Hematology/Oncology Pharmacy Association (HOPA) has awarded two HOPA Research Grant Awards to Val Adams, PharmD, BCOP, FCCP, and Jill S. Bates, PharmD, MS, BCOP, for their respective research projects. The goal of HOPA’s Research Grant efforts are to fund work that results in facilitating...
Low-Dose Chemical Exposure and Cancer
According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Clinical Trials Actively Recruiting Patients With Liver Cancer
Pilot Study Title: Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma Study Type: Interventional/nonrandomized/parallel assignment Study Sponsor and Collaborators: Washington University School of Medicine Purpose: ...
Multi-Institutional Metastatic Melanoma Research Team Receives $900,000 L’Oréal Paris USA–MRA Team Science Award for Women in Scientific Research
An international, multi-institutional research team consisting of the Spanish National Cancer Research Centre (CNIO); The Wistar Institute; Cancer Research UK Edinburgh Centre; the Perelman School of Medicine at the University of Pennsylvania; and the Icahn School of Medicine at Mount Sinai has...
